- Technical notes
- Selection guides
Advancing diabetes research and drug development with human iPSC-derived beta cells
Diabetes is a major health and financial burden. In the US alone, 30 million people have diabetes, and the number is rapidly growing. As the prevalence of diabetes continues to increase, so does the need for novel drugs that are effective at treating and ultimately curing the disease. In vitro beta cell models play a crucial role in diabetes research and drug development. However, current beta cell models have several limitations that affect the data generated from them and thereby limit their utility. In order to continue to make advances, researchers need a better model—one that is inexpensive, readily available, and physiologically and functionally relevant.
In this webinar, Dr. Brenda Huang of Takara Bio USA, Inc. describes an improved, hiPSC-derived beta cell model that addresses the shortcomings of commonly used beta cell models. Cellartis hiPS beta cells provide an unlimited supply of mature, functional cells, and a more accurate, relevant model for diabetes research and drug development.
- Prevalence and impact of diabetes
- The role of beta cells in diabetes
- Limitations of current models for studying beta-cell function
- Advantages of Cellartis hiPS beta cells for diabetes research and drug discovery
- Demonstration of physiologically relevant responses to drugs that target the insulin pathway
Sign up to watch the webinar
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.